CMD1A
MCID: CRD093
MIFTS: 49

Cardiomyopathy, Dilated, 1a (CMD1A)

Categories: Blood diseases, Cardiovascular diseases, Ear diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Cardiomyopathy, Dilated, 1a

MalaCards integrated aliases for Cardiomyopathy, Dilated, 1a:

Name: Cardiomyopathy, Dilated, 1a 57 13
Dilated Cardiomyopathy 1a 12 29 6 15
Cmd1a 57 12 75
Cdcd1 57 12 75
Cardiomyopathy, Familial Idiopathic 57 73
Familial Dilated Cardiomyopathy with Conduction Defect Due to Lmna Mutation 12
Cardiomyopathy, Dilated, with Conduction Defect 1; Cdcd1 57
Cardiomyopathy Dilated with Conduction Defect Type 1 53
Cardiomyopathy, Dilated, with Conduction Defect 1 57
Dilated Cardiomyopathy with Conduction Defect 1 12
Cardiomyopathy Dilated with Conduction Defect 1 75
Cardiomyopathy, Idiopathic Dilated 57
Cardiomyopathy, Dilated, Type 1a 40
Cardiomyopathy, Congestive 57
Cardiomyopathy, Dilated 1a 75

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant
? a recessive form also


HPO:

32
cardiomyopathy, dilated, 1a:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 115200
Disease Ontology 12 DOID:0110425
MedGen 42 C1449563
MeSH 44 D002311
UMLS 73 C1449563

Summaries for Cardiomyopathy, Dilated, 1a

OMIM : 57 Dilated cardiomyopathy (CMD) is characterized by cardiac dilatation and reduced systolic function. CMD is the most frequent form of cardiomyopathy and accounts for more than half of all cardiac transplantations performed in patients between 1 and 10 years of age. A heritable pattern is present in 20 to 30% of cases. Most familial CMD pedigrees show an autosomal dominant pattern of inheritance, usually presenting in the second or third decade of life (summary by Levitas et al., 2010). (115200)

MalaCards based summary : Cardiomyopathy, Dilated, 1a, also known as dilated cardiomyopathy 1a, is related to dilated cardiomyopathy and muscular dystrophy, congenital merosin-deficient, 1a. An important gene associated with Cardiomyopathy, Dilated, 1a is LMNA (Lamin A/C), and among its related pathways/superpathways are Pathways in cancer and Allograft rejection. The drugs Morphine and Acetaminophen have been mentioned in the context of this disorder. Affiliated tissues include heart, and related phenotypes are congestive heart failure and dilated cardiomyopathy

Disease Ontology : 12 A dilated cardiomyopathy that has material basis in mutation in the LMNA gene on chromosome 1q21.

UniProtKB/Swiss-Prot : 75 Cardiomyopathy, dilated 1A: A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.

Related Diseases for Cardiomyopathy, Dilated, 1a

Diseases in the Dilated Cardiomyopathy family:

Cardiomyopathy, Dilated, 1a Cardiomyopathy, Dilated, 3b
Cardiomyopathy, Dilated, 1b Cardiomyopathy, Dilated, 1e
Cardiomyopathy, Dilated, 1d Cardiomyopathy, Dilated, 1g
Cardiomyopathy, Dilated, 1h Cardiomyopathy, Dilated, 1i
Cardiomyopathy, Dilated, 1j Cardiomyopathy, Dilated, 1k
Cardiomyopathy, Dilated, 1l Cardiomyopathy, Dilated, 1m
Cardiomyopathy, Dilated, 1o Cardiomyopathy, Dilated, 1p
Cardiomyopathy, Dilated, 1q Cardiomyopathy, Dilated, 1w
Cardiomyopathy, Dilated, 1x Cardiomyopathy, Dilated, 1z
Cardiomyopathy, Dilated, 2a Cardiomyopathy, Dilated, 1bb
Cardiomyopathy, Dilated, 1cc Cardiomyopathy, Dilated, 1dd
Cardiomyopathy, Dilated, 1ee Cardiomyopathy, Dilated, 1ff
Cardiomyopathy, Dilated, 1r Cardiomyopathy, Dilated, 1gg
Cardiomyopathy, Dilated, 1u Cardiomyopathy, Dilated, 1v
Cardiomyopathy, Dilated, 1hh Cardiomyopathy, Dilated, 2b
Cardiomyopathy, Dilated, 1ii Cardiomyopathy, Dilated, 1jj
Cardiomyopathy, Dilated, 1kk Cardiomyopathy, Dilated, 1nn
Autoimmune Cardiomyopathy Dilated Cardiomyopathy 1t
Lmna-Related Dilated Cardiomyopathy Cardiomyopathy Due to Anthracyclines

Diseases related to Cardiomyopathy, Dilated, 1a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Related Disease Score Top Affiliating Genes
1 dilated cardiomyopathy 32.2 LMNA LDB3 LAMA2 EMD DMD DAG1
2 muscular dystrophy, congenital merosin-deficient, 1a 31.7 LMNA LAMA2 DMD DAG1
3 cardiomyopathy, dilated, 1h 30.0 SNCA LMNA EMD
4 cardiomyopathy, dilated, with hypergonadotropic hypogonadism 11.3
5 cardiomyopathy, dilated, 2a 11.2
6 cardiomyopathy, dilated, 1l 11.1
7 emerinopathy 10.2 LMNA EMD
8 familial isolated arrhythmogenic ventricular dysplasia, left dominant form 10.2 LMNA LDB3
9 familial isolated arrhythmogenic ventricular dysplasia, biventricular form 10.2 LMNA LDB3
10 familial isolated arrhythmogenic ventricular dysplasia, right dominant form 10.2 LMNA LDB3
11 myopathy, proximal, and ophthalmoplegia 10.2 LMNA EMD
12 emery-dreifuss muscular dystrophy 1, x-linked 10.2 LMNA EMD
13 autosomal dominant limb-girdle muscular dystrophy 10.2 LMNA EMD
14 autosomal dominant limb-girdle muscular dystrophy type 1b 10.1 LMNA EMD
15 pelger-huet anomaly 10.1 LMNA EMD
16 isolated hyperckemia 10.0 LAMA2 DMD
17 myopathy, x-linked, with excessive autophagy 10.0 LAMA2 EMD DMD
18 congenital fiber-type disproportion 10.0 LMNA EMD DMD
19 atrial standstill 1 10.0 LMNA EMD DMD
20 creatine phosphokinase, elevated serum 10.0 LAMA2 DMD
21 myofibrillar myopathy 10.0 LMNA LDB3 DMD
22 muscular dystrophy-dystroglycanopathy , type a, 1 10.0 LAMA2 DMD DAG1
23 muscular dystrophy-dystroglycanopathy , type a, 4 10.0 DAG1 DMD LAMA2
24 muscular dystrophy-dystroglycanopathy , type b, 6 10.0 DAG1 DMD LAMA2
25 long qt syndrome 1 9.9 CALM3 CALM2 CALM1
26 long qt syndrome 15 9.9 CALM3 CALM2 CALM1
27 long qt syndrome 9.9 CALM3 CALM2 CALM1
28 external ear disease 9.9 CALM3 CALM2 CALM1
29 otomycosis 9.9 CALM3 CALM2 CALM1
30 otitis externa 9.9 CALM3 CALM2 CALM1
31 sporotrichosis 9.9 CALM3 CALM2 CALM1
32 emery-dreifuss muscular dystrophy 5, autosomal dominant 9.9 CALM3 CALM2 CALM1
33 spontaneous ocular nystagmus 9.9 CALM3 CALM2 CALM1
34 deafness, autosomal recessive 44 9.9 CALM3 CALM2 CALM1
35 acute dacryocystitis 9.9 CALM3 CALM2 CALM1
36 dystonia 24 9.9 CALM3 CALM2 CALM1
37 gestational choriocarcinoma 9.9 CALM3 CALM2 CALM1
38 triosephosphate isomerase deficiency 9.9 CALM3 CALM2 CALM1
39 tinea unguium 9.9 CALM3 CALM2 CALM1
40 leber congenital amaurosis 2 9.9 CALM3 CALM2 CALM1
41 clear cell acanthoma 9.9 CALM3 CALM2 CALM1
42 primary systemic mycosis 9.9 CALM3 CALM2 CALM1
43 cardiomyopathy, dilated, 1p 9.9 CALM3 CALM2 CALM1
44 phaeohyphomycosis 9.9 CALM2 CALM3 CALM1
45 deafness, autosomal dominant 2a 9.9 CALM1 CALM2 CALM3
46 microcephaly 2, primary, autosomal recessive, with or without cortical malformations 9.9 CALM1 CALM2 CALM3
47 neuromuscular disease 9.9 LMNA LAMA2 EMD DMD
48 ceroid lipofuscinosis, neuronal, 11 9.9 CALM1 CALM2 CALM3
49 walker-warburg syndrome 9.9 LAMA2 DMD DAG1
50 primary cutaneous amyloidosis 9.9 CALM3 CALM2 CALM1

Graphical network of the top 20 diseases related to Cardiomyopathy, Dilated, 1a:



Diseases related to Cardiomyopathy, Dilated, 1a

Symptoms & Phenotypes for Cardiomyopathy, Dilated, 1a

Symptoms via clinical synopsis from OMIM:

57
Cardiac:
congestive heart failure
pericardial effusion
ventricular arrhythmia
congestive cardiomyopathy
conduction defects
more
Lab:
myocardial deposits of a nonmetachromatic, diastase-resistant, pas-positive polysaccharide
defect in suppressor lymphocyte function

Neuro:
normal neurologic examination
adams-stokes attacks


Clinical features from OMIM:

115200

Human phenotypes related to Cardiomyopathy, Dilated, 1a:

32 (show all 6)
# Description HPO Frequency HPO Source Accession
1 congestive heart failure 32 HP:0001635
2 dilated cardiomyopathy 32 HP:0001644
3 atrial fibrillation 32 HP:0005110
4 pericardial effusion 32 HP:0001698
5 ventricular arrhythmia 32 HP:0004308
6 atrial flutter 32 HP:0004749

MGI Mouse Phenotypes related to Cardiomyopathy, Dilated, 1a:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 DAG1 DMD EMD HAND2 HPGDS LAMA2
2 cellular MP:0005384 9.76 DAG1 DMD EMD HAND2 HPGDS LAMA2
3 homeostasis/metabolism MP:0005376 9.65 DAG1 DMD EMD HAND2 HPGDS LAMA2
4 muscle MP:0005369 9.17 DAG1 DMD EMD HAND2 LAMA2 LDB3

Drugs & Therapeutics for Cardiomyopathy, Dilated, 1a

Drugs for Cardiomyopathy, Dilated, 1a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Morphine Approved, Investigational Phase 4 57-27-2 5288826
2
Acetaminophen Approved Phase 4 103-90-2 1983
3
Vancomycin Approved Phase 4 1404-90-6 14969 441141
4
Cefazolin Approved Phase 4 25953-19-9 656510 33255
5
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
6
Lopinavir Approved Phase 4,Phase 3,Phase 2 192725-17-0 92727
7
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 155213-67-5 392622
8
Nelfinavir Approved Phase 4,Phase 3,Phase 2,Not Applicable 159989-64-7 64143
9
Doxazosin Approved Phase 4 74191-85-8 3157
10
Metoprolol Approved, Investigational Phase 4,Phase 2 37350-58-6, 51384-51-1 4171
11
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
12
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
13
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
14
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
15
Adenosine Approved, Investigational Phase 4 58-61-7 60961
16
Regadenoson Approved, Investigational Phase 4 313348-27-5 219024
17
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 44475014
18
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
19
leucovorin Approved Phase 4 58-05-9 6006 143
20
Iron Approved Phase 4 7439-89-6 23925
21
Verapamil Approved Phase 4 52-53-9 2520
22
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 134678-17-4 60825
23
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
24
Abacavir Approved, Investigational Phase 4,Phase 2 136470-78-5 65140 441300
25
Stavudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3056-17-5 18283
26
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
27
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
28
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
29
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
30
Cobalamin Experimental Phase 4 13408-78-1 6438156
31 Analgesics, Non-Narcotic Phase 4
32 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Not Applicable
33 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
34 Analgesics Phase 4,Phase 3,Phase 2,Not Applicable
35 Antipyretics Phase 4
36 Narcotics Phase 4,Phase 3,Phase 2,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
38 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
41 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Reverse Transcriptase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
46 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
49
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Calcium, Dietary Phase 4,Phase 1,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Study Comparing Reduction in Pain Intensity Following IV or Oral Acetaminophen Unknown status NCT02678416 Phase 4 IV Acetaminophen;IV Morphine;Acetaminophen tablets
2 The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection Unknown status NCT02307006 Phase 4 Ceftaroline;Cefazolin / Vancomycin
3 Immune Reconstitution as a Determinant of Adverse Effects to New Antiretroviral Therapy in Persons With Advanced HIV Infection Unknown status NCT00885664 Phase 4 Truvada (tenofovir/emitricitabine);Kaletra (lopinavir/ritonavir)
4 Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Completed NCT02115581 Phase 4 Coenzyme Q10;Placebo
5 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Completed NCT01798992 Phase 4 Carvedilol;Metoprolol succinate;Metoprolol succinate + doxazosin
6 Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Completed NCT01917149 Phase 4 Benazepril;Valsartan;Metoprolol
7 Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Recruiting NCT03249272 Phase 4 Regadenoson;Adenosine
8 Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. Completed NCT02031289 Phase 4 Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
9 Pulse Reduction On Beta-blocker and Ivabradine Therapy Recruiting NCT02973594 Phase 4 Ivabradine;Placebo
10 Kuvan®'s Effect on the Cognition of Children With Phenylketonuria Active, not recruiting NCT01965912 Phase 4 Kuvan®
11 3TC or No 3TC for HIV With 3TC Resistance Suspended NCT00143728 Phase 4 Lamivudine
12 A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients Completed NCT00005106 Phase 4 Lamivudine/Zidovudine;Abacavir sulfate;Nelfinavir mesylate;Lamivudine;Stavudine
13 Chlorhexidine Cordcare for Reduction in Neonatal Mortality and Omphalitis Unknown status NCT01528852 Phase 3 Chlorhexidine 4%;Chlorhexidine 4%
14 Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection Unknown status NCT00017784 Phase 3 Valganciclovir
15 A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Unknown status NCT00005663 Phase 3 Valacyclovir hydrochloride
16 Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure Unknown status NCT00025727 Phase 3 Lopinavir/Ritonavir;Ritonavir;GW433908
17 Honey in Idiopathic Dilated Cardiomyopathy Completed NCT02987322 Phase 2, Phase 3
18 Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer Completed NCT02609321 Phase 3
19 The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution Completed NCT00741156 Phase 3 Enalaprilat
20 Clinical Evaluation Of The PARADYM RF Device Completed NCT01193634 Phase 3
21 Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) Completed NCT01600716 Phase 3 Placebo (Normal Saline)
22 Cognitive Behavioral Therapy (CBT) for Posttraumatic Stress Disorder (PTSD) in Community Addiction Treatment Completed NCT01457391 Phase 3
23 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine Completed NCT02357901 Phase 3 SUBOXONE;RBP-6000;Placebo
24 Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients Completed NCT01852045 Phase 3
25 Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity Active, not recruiting NCT02849418 Phase 3 GSK1358820;Placebo
26 Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 Active, not recruiting NCT02660138 Phase 3 AbobotulinumtoxinA;AbobotulinumtoxinA;AbobotulinumtoxinA Placebo;AbobotulinumtoxinA Placebo
27 A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB) Enrolling by invitation NCT02786407 Phase 3 Botulinum Toxin Type A for Injection;Placebo
28 CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D) Active, not recruiting NCT03263494 Phase 3
29 Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients Completed NCT00005918 Phase 3 Efavirenz;Lamivudine;Stavudine
30 Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor Completed NCT00038519 Phase 2, Phase 3 Amprenavir/ritonavir;Saquinavir/ritonavir
31 Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s) Completed NCT00028301 Phase 3 Atazanavir;Lopinavir/Ritonavir
32 A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor Terminated NCT00028067 Phase 3 Atazanavir;Nelfinavir mesylate
33 T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs Completed NCT00008528 Phase 3 Enfuvirtide
34 Effectiveness of an HIV Vaccine in HIV-Negative Adults in North America Who Are at Risk of HIV Infection Completed NCT00002441 Phase 3
35 A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients Completed NCT00002378 Phase 3 Ritonavir;Nelfinavir mesylate;Saquinavir;Delavirdine mesylate;Lamivudine;Stavudine;Zidovudine
36 Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Unknown status NCT01957826 Phase 1, Phase 2
37 Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Unknown status NCT01219452 Phase 1, Phase 2
38 Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy Unknown status NCT02354911 Phase 2
39 Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy Unknown status NCT01947569 Phase 1, Phase 2
40 Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study Unknown status NCT00885495 Phase 1, Phase 2 darunavir, ritonavir, rosuvastatin;rosuvastatin, darunavir, ritonavir
41 TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1 Unknown status NCT00089700 Phase 2 TNX-355
42 The Safety and Effectiveness of Indinavir Plus Ritonavir Plus Two NRTIs in HIV-Infected Patients Who Need Early Intervention Treatment Unknown status NCT00005118 Phase 2 Indinavir sulfate;Ritonavir
43 Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Recruiting NCT02033278 Phase 2 Infusion of autologous mononuclear bone marrow cells;Placebo infusion
44 Optimal Treatment of Veterans With PTSD and Comorbid OUD Recruiting NCT03605342 Phase 2 Buprenorphine
45 Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy Completed NCT02256501 Phase 1, Phase 2
46 Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy Withdrawn NCT00281255 Phase 1, Phase 2 Allopurinol;Dobutamine
47 Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Completed NCT00629096 Phase 2
48 PET Scan to Determine Areas of Blood Flow and Activity in the Hearts of Patients With Heart Disease Taking Beta-Blockers Completed NCT00001402 Phase 2
49 Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Completed NCT01302171 Phase 2 granulocyte colony stimulating factor (GCSF)
50 Fathers for Change for Men With Co-occurring Domestic Violence and Substance Abuse Completed NCT01385553 Phase 1, Phase 2

Search NIH Clinical Center for Cardiomyopathy, Dilated, 1a

Genetic Tests for Cardiomyopathy, Dilated, 1a

Genetic tests related to Cardiomyopathy, Dilated, 1a:

# Genetic test Affiliating Genes
1 Dilated Cardiomyopathy 1a 29 LMNA

Anatomical Context for Cardiomyopathy, Dilated, 1a

MalaCards organs/tissues related to Cardiomyopathy, Dilated, 1a:

41
Heart

Publications for Cardiomyopathy, Dilated, 1a

Articles related to Cardiomyopathy, Dilated, 1a:

# Title Authors Year
1
Gene symbol: LMNA. Disease: cardiomyopathy, dilated, with conduction defect 1. ( 16156025 )
2005

Variations for Cardiomyopathy, Dilated, 1a

UniProtKB/Swiss-Prot genetic disease variations for Cardiomyopathy, Dilated, 1a:

75 (show all 28)
# Symbol AA change Variation ID SNP ID
1 LMNA p.Leu85Arg VAR_009975 rs28933090
2 LMNA p.Asn195Lys VAR_009977 rs28933091
3 LMNA p.Glu203Gly VAR_009978 rs28933092
4 LMNA p.Glu161Lys VAR_017660 rs28933093
5 LMNA p.Arg60Gly VAR_034706 rs28928900
6 LMNA p.Arg89Leu VAR_039758 rs59040894
7 LMNA p.Lys97Glu VAR_039759 rs59065411
8 LMNA p.Ser143Pro VAR_039761 rs61661343
9 LMNA p.Arg190Gln VAR_039763 rs267607571
10 LMNA p.Arg190Trp VAR_039764 rs59026483
11 LMNA p.Asp192Gly VAR_039765 rs57045855
12 LMNA p.Glu203Lys VAR_039767 rs61195471
13 LMNA p.Leu215Pro VAR_039768 rs61295588
14 LMNA p.Glu317Lys VAR_039775 rs56816490
15 LMNA p.Arg349Leu VAR_039776 rs58789393
16 LMNA p.Arg399Cys VAR_039778 rs58672172
17 LMNA p.Arg435Cys VAR_039779 rs150840924
18 LMNA p.Arg541Cys VAR_039786 rs56984562
19 LMNA p.Arg541Ser VAR_039788 rs56984562
20 LMNA p.Ser573Leu VAR_039789 rs60890628
21 LMNA p.Leu92Phe VAR_067257 rs267607560
22 LMNA p.Gly523Arg VAR_067258 rs201583907
23 LMNA p.Arg101Pro VAR_070174 rs267607568
24 LMNA p.Arg166Pro VAR_070176 rs267607570
25 LMNA p.Ile210Ser VAR_070177 rs267607572
26 LMNA p.Ala318Thr VAR_070179 rs267607574
27 LMNA p.Arg388His VAR_070180 rs267607576
28 LMNA p.Arg471His VAR_070182 rs267607578

ClinVar genetic disease variations for Cardiomyopathy, Dilated, 1a:

6 (show top 50) (show all 87)
# Gene Variation Type Significance SNP ID Assembly Location
1 LMNA NM_170707.3(LMNA): c.178C> G (p.Arg60Gly) single nucleotide variant Pathogenic rs28928900 GRCh37 Chromosome 1, 156084887: 156084887
2 LMNA NM_170707.3(LMNA): c.178C> G (p.Arg60Gly) single nucleotide variant Pathogenic rs28928900 GRCh38 Chromosome 1, 156115096: 156115096
3 LMNA NM_170707.3(LMNA): c.254T> G (p.Leu85Arg) single nucleotide variant Pathogenic rs28933090 GRCh37 Chromosome 1, 156084963: 156084963
4 LMNA NM_170707.3(LMNA): c.254T> G (p.Leu85Arg) single nucleotide variant Pathogenic rs28933090 GRCh38 Chromosome 1, 156115172: 156115172
5 LMNA NM_170707.3(LMNA): c.585C> G (p.Asn195Lys) single nucleotide variant Pathogenic rs28933091 GRCh37 Chromosome 1, 156104265: 156104265
6 LMNA NM_170707.3(LMNA): c.585C> G (p.Asn195Lys) single nucleotide variant Pathogenic rs28933091 GRCh38 Chromosome 1, 156134474: 156134474
7 LMNA NM_170707.3(LMNA): c.608A> G (p.Glu203Gly) single nucleotide variant Pathogenic rs28933092 GRCh37 Chromosome 1, 156104288: 156104288
8 LMNA NM_170707.3(LMNA): c.608A> G (p.Glu203Gly) single nucleotide variant Pathogenic rs28933092 GRCh38 Chromosome 1, 156134497: 156134497
9 LMNA NM_005572.3(LMNA): c.1711C> A (p.Arg571Ser) single nucleotide variant Uncertain significance rs80338938 GRCh37 Chromosome 1, 156107547: 156107547
10 LMNA NM_005572.3(LMNA): c.1711C> A (p.Arg571Ser) single nucleotide variant Uncertain significance rs80338938 GRCh38 Chromosome 1, 156137756: 156137756
11 LMNA NM_005572.3(LMNA): c.959delT (p.Arg321Glufs) deletion Pathogenic rs56771886 GRCh37 Chromosome 1, 156105714: 156105714
12 LMNA NM_005572.3(LMNA): c.959delT (p.Arg321Glufs) deletion Pathogenic rs56771886 GRCh38 Chromosome 1, 156135923: 156135923
13 LMNA NM_170707.3(LMNA): c.1130G> A (p.Arg377His) single nucleotide variant Pathogenic rs61672878 GRCh37 Chromosome 1, 156105885: 156105885
14 LMNA NM_170707.3(LMNA): c.1130G> A (p.Arg377His) single nucleotide variant Pathogenic rs61672878 GRCh38 Chromosome 1, 156136094: 156136094
15 LMNA NM_170707.3(LMNA): c.481G> A (p.Glu161Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933093 GRCh37 Chromosome 1, 156100532: 156100532
16 LMNA NM_170707.3(LMNA): c.481G> A (p.Glu161Lys) single nucleotide variant Pathogenic/Likely pathogenic rs28933093 GRCh38 Chromosome 1, 156130741: 156130741
17 LMNA NM_170707.3(LMNA): c.1718C> T (p.Ser573Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs60890628 GRCh37 Chromosome 1, 156108298: 156108298
18 LMNA NM_170707.3(LMNA): c.1718C> T (p.Ser573Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs60890628 GRCh38 Chromosome 1, 156138507: 156138507
19 LMNA NM_170707.3(LMNA): c.1072G> A (p.Glu358Lys) single nucleotide variant Pathogenic rs60458016 GRCh37 Chromosome 1, 156105827: 156105827
20 LMNA NM_170707.3(LMNA): c.1072G> A (p.Glu358Lys) single nucleotide variant Pathogenic rs60458016 GRCh38 Chromosome 1, 156136036: 156136036
21 LMNA NM_170707.3(LMNA): c.1621C> G (p.Arg541Gly) single nucleotide variant Pathogenic rs56984562 GRCh37 Chromosome 1, 156107457: 156107457
22 LMNA NM_170707.3(LMNA): c.1621C> G (p.Arg541Gly) single nucleotide variant Pathogenic rs56984562 GRCh38 Chromosome 1, 156137666: 156137666
23 LMNA NM_005572.3(LMNA): c.1003C> T (p.Arg335Trp) single nucleotide variant Pathogenic/Likely pathogenic rs386134243 GRCh37 Chromosome 1, 156105758: 156105758
24 LMNA NM_005572.3(LMNA): c.1003C> T (p.Arg335Trp) single nucleotide variant Pathogenic/Likely pathogenic rs386134243 GRCh38 Chromosome 1, 156135967: 156135967
25 LMNA NM_170707.3(LMNA): c.1412G> A (p.Arg471His) single nucleotide variant Conflicting interpretations of pathogenicity rs267607578 GRCh37 Chromosome 1, 156106743: 156106743
26 LMNA NM_170707.3(LMNA): c.1412G> A (p.Arg471His) single nucleotide variant Conflicting interpretations of pathogenicity rs267607578 GRCh38 Chromosome 1, 156136952: 156136952
27 MYBPC3 NM_000256.3(MYBPC3): c.977G> A (p.Arg326Gln) single nucleotide variant Benign/Likely benign rs34580776 GRCh37 Chromosome 11, 47367871: 47367871
28 MYBPC3 NM_000256.3(MYBPC3): c.977G> A (p.Arg326Gln) single nucleotide variant Benign/Likely benign rs34580776 GRCh38 Chromosome 11, 47346320: 47346320
29 LMNA NM_170707.3(LMNA): c.1129C> T (p.Arg377Cys) single nucleotide variant Pathogenic/Likely pathogenic rs397517889 GRCh37 Chromosome 1, 156105884: 156105884
30 LMNA NM_170707.3(LMNA): c.1129C> T (p.Arg377Cys) single nucleotide variant Pathogenic/Likely pathogenic rs397517889 GRCh38 Chromosome 1, 156136093: 156136093
31 LMNA NM_170707.3(LMNA): c.1146C> T (p.Gly382=) single nucleotide variant Pathogenic/Likely pathogenic rs57508089 GRCh37 Chromosome 1, 156105901: 156105901
32 LMNA NM_170707.3(LMNA): c.1146C> T (p.Gly382=) single nucleotide variant Pathogenic/Likely pathogenic rs57508089 GRCh38 Chromosome 1, 156136110: 156136110
33 LMNA NM_170707.3(LMNA): c.1621C> T (p.Arg541Cys) single nucleotide variant Pathogenic/Likely pathogenic rs56984562 GRCh37 Chromosome 1, 156107457: 156107457
34 LMNA NM_170707.3(LMNA): c.1621C> T (p.Arg541Cys) single nucleotide variant Pathogenic/Likely pathogenic rs56984562 GRCh38 Chromosome 1, 156137666: 156137666
35 LMNA NM_170707.3(LMNA): c.607G> A (p.Glu203Lys) single nucleotide variant Pathogenic rs61195471 GRCh37 Chromosome 1, 156104287: 156104287
36 LMNA NM_170707.3(LMNA): c.607G> A (p.Glu203Lys) single nucleotide variant Pathogenic rs61195471 GRCh38 Chromosome 1, 156134496: 156134496
37 LMNA NM_005572.3(LMNA): c.673C> T (p.Arg225Ter) single nucleotide variant Pathogenic rs60682848 GRCh37 Chromosome 1, 156104629: 156104629
38 LMNA NM_005572.3(LMNA): c.673C> T (p.Arg225Ter) single nucleotide variant Pathogenic rs60682848 GRCh38 Chromosome 1, 156134838: 156134838
39 LMNA NM_170707.3(LMNA): c.644T> C (p.Leu215Pro) single nucleotide variant Pathogenic rs61295588 GRCh37 Chromosome 1, 156104600: 156104600
40 LMNA NM_170707.3(LMNA): c.644T> C (p.Leu215Pro) single nucleotide variant Pathogenic rs61295588 GRCh38 Chromosome 1, 156134809: 156134809
41 LMNA NM_170707.3(LMNA): c.1149G> A (p.Glu383=) single nucleotide variant Conflicting interpretations of pathogenicity rs267607603 GRCh37 Chromosome 1, 156105904: 156105904
42 LMNA NM_170707.3(LMNA): c.1149G> A (p.Glu383=) single nucleotide variant Conflicting interpretations of pathogenicity rs267607603 GRCh38 Chromosome 1, 156136113: 156136113
43 LMNA NM_170707.3(LMNA): c.1609-3C> G single nucleotide variant Pathogenic/Likely pathogenic rs267607581 GRCh37 Chromosome 1, 156107442: 156107442
44 LMNA NM_170707.3(LMNA): c.1609-3C> G single nucleotide variant Pathogenic/Likely pathogenic rs267607581 GRCh38 Chromosome 1, 156137651: 156137651
45 LMNA NM_170707.3(LMNA): c.1622G> C (p.Arg541Pro) single nucleotide variant Pathogenic/Likely pathogenic rs61444459 GRCh37 Chromosome 1, 156107458: 156107458
46 LMNA NM_170707.3(LMNA): c.1622G> C (p.Arg541Pro) single nucleotide variant Pathogenic/Likely pathogenic rs61444459 GRCh38 Chromosome 1, 156137667: 156137667
47 LMNA NM_170707.3(LMNA): c.29C> T (p.Thr10Ile) single nucleotide variant Pathogenic/Likely pathogenic rs57077886 GRCh37 Chromosome 1, 156084738: 156084738
48 LMNA NM_170707.3(LMNA): c.29C> T (p.Thr10Ile) single nucleotide variant Pathogenic/Likely pathogenic rs57077886 GRCh38 Chromosome 1, 156114947: 156114947
49 LMNA NM_170707.3(LMNA): c.302G> C (p.Arg101Pro) single nucleotide variant Uncertain significance rs267607568 GRCh37 Chromosome 1, 156085011: 156085011
50 LMNA NM_170707.3(LMNA): c.302G> C (p.Arg101Pro) single nucleotide variant Uncertain significance rs267607568 GRCh38 Chromosome 1, 156115220: 156115220

Expression for Cardiomyopathy, Dilated, 1a

Search GEO for disease gene expression data for Cardiomyopathy, Dilated, 1a.

Pathways for Cardiomyopathy, Dilated, 1a

Pathways related to Cardiomyopathy, Dilated, 1a according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1 12.75 CALM1 CALM2 CALM3 LAMA2
2
Show member pathways
12.67 CALM1 CALM2 CALM3 DAG1 DMD LAMA2
3
Show member pathways
12.18 CALM1 CALM2 CALM3
4
Show member pathways
12.17 CALM1 CALM2 CALM3
5
Show member pathways
12.15 CALM1 CALM2 CALM3
6 12.14 CALM1 CALM2 CALM3
7
Show member pathways
12.13 CALM1 CALM2 CALM3
8
Show member pathways
12.13 CALM1 CALM2 CALM3
9
Show member pathways
12.1 CALM1 CALM2 CALM3
10
Show member pathways
12.1 CALM1 CALM2 CALM3
11
Show member pathways
12.08 CALM1 CALM2 CALM3
12 12.08 CALM1 CALM2 CALM3
13
Show member pathways
12.07 CALM1 CALM2 CALM3
14
Show member pathways
12.06 DAG1 DMD EMD LAMA2 LMNA
15
Show member pathways
12.04 CALM1 CALM2 CALM3
16 12.01 CALM1 CALM2 CALM3
17 12 CALM1 CALM2 CALM3
18
Show member pathways
11.94 CALM1 CALM2 CALM3
19
Show member pathways
11.93 CALM1 CALM2 CALM3
20
Show member pathways
11.9 CALM1 CALM2 CALM3
21
Show member pathways
11.87 CALM1 CALM2 CALM3
22 11.85 CALM1 CALM2 CALM3
23 11.85 CALM1 CALM2 CALM3
24 11.82 CALM1 CALM2 CALM3
25
Show member pathways
11.82 CALM1 CALM2 CALM3
26
Show member pathways
11.79 CALM1 CALM2 CALM3
27
Show member pathways
11.79 CALM1 CALM2 CALM3
28
Show member pathways
11.72 CALM1 CALM2 CALM3
29
Show member pathways
11.71 CALM1 CALM2 CALM3
30
Show member pathways
11.69 CALM1 CALM2 CALM3
31 11.69 CALM1 CALM2 CALM3
32
Show member pathways
11.67 CALM1 CALM2 CALM3
33 11.66 CALM1 CALM2 CALM3
34
Show member pathways
11.61 CALM1 CALM2 CALM3
35
Show member pathways
11.61 DAG1 DMD LAMA2
36 11.59 CALM1 CALM2 CALM3
37
Show member pathways
11.59 DAG1 DMD EMD LAMA2 LMNA
38 11.56 CALM1 CALM2 CALM3
39
Show member pathways
11.56 CALM1 CALM2 CALM3 DAG1 DMD LMNA
40
Show member pathways
11.55 CALM1 CALM2 CALM3
41 11.5 CALM1 CALM2 CALM3
42 11.49 CALM1 CALM2 CALM3
43 11.46 CALM1 CALM2 CALM3
44 11.45 CALM1 CALM2 CALM3
45 11.31 CALM1 CALM2 CALM3 HAND2
46 11.3 CALM1 CALM2 CALM3
47 11.29 CALM1 CALM2 CALM3
48 11.27 CALM1 CALM2 CALM3
49 11.23 CALM1 CALM2 CALM3
50 11.22 CALM1 CALM2 CALM3

GO Terms for Cardiomyopathy, Dilated, 1a

Cellular components related to Cardiomyopathy, Dilated, 1a according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 cytoskeleton GO:0005856 9.91 CALM1 CALM2 CALM3 DAG1 DMD LDB3
2 nuclear envelope GO:0005635 9.74 EMD LMNA SREBF1
3 protein-containing complex GO:0032991 9.73 CALM1 CALM2 CALM3 DMD HAND2 SREBF1
4 vesicle GO:0031982 9.72 CALM1 CALM2 CALM3
5 myelin sheath GO:0043209 9.71 CALM1 CALM2 CALM3
6 spindle GO:0005819 9.71 CALM1 CALM2 CALM3 EMD
7 growth cone GO:0030426 9.67 CALM1 CALM3 SNCA
8 spindle pole GO:0000922 9.65 CALM1 CALM2 CALM3
9 sarcolemma GO:0042383 9.63 DAG1 DMD LAMA2
10 sarcomere GO:0030017 9.61 CALM1 CALM2 CALM3
11 nuclear outer membrane GO:0005640 9.56 EMD SNCA
12 costamere GO:0043034 9.52 DAG1 DMD
13 dystrophin-associated glycoprotein complex GO:0016010 9.51 DAG1 DMD
14 spindle microtubule GO:0005876 9.5 CALM1 CALM2 CALM3
15 calcium channel complex GO:0034704 9.33 CALM1 CALM2 CALM3
16 synaptic vesicle membrane GO:0030672 9.26 CALM1 CALM3 DMD SNCA
17 catalytic complex GO:1902494 8.8 CALM1 CALM2 CALM3

Biological processes related to Cardiomyopathy, Dilated, 1a according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 aging GO:0007568 9.9 DAG1 DMD SNCA SREBF1
2 muscle organ development GO:0007517 9.82 DMD EMD LAMA2
3 calcium-mediated signaling GO:0019722 9.8 CALM1 CALM2 CALM3
4 response to calcium ion GO:0051592 9.78 CALM1 CALM2 CALM3
5 substantia nigra development GO:0021762 9.77 CALM1 CALM2 CALM3
6 regulation of cytokinesis GO:0032465 9.76 CALM1 CALM2 CALM3
7 positive regulation of peptidyl-threonine phosphorylation GO:0010800 9.74 CALM1 CALM2 CALM3
8 positive regulation of protein dephosphorylation GO:0035307 9.73 CALM1 CALM2 CALM3
9 positive regulation of protein autophosphorylation GO:0031954 9.72 CALM1 CALM2 CALM3
10 regulation of cardiac muscle contraction GO:0055117 9.71 CALM1 CALM2 CALM3
11 regulation of ryanodine-sensitive calcium-release channel activity GO:0060314 9.7 CALM1 CALM3 DMD
12 negative regulation of peptidyl-threonine phosphorylation GO:0010801 9.69 CALM1 CALM2 CALM3
13 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.67 CALM1 CALM2 CALM3
14 positive regulation of protein serine/threonine kinase activity GO:0071902 9.67 CALM1 CALM2 CALM3 SNCA
15 positive regulation of DNA binding GO:0043388 9.66 CALM2 CALM3
16 skeletal muscle tissue regeneration GO:0043403 9.66 DAG1 DMD
17 positive regulation of nitric-oxide synthase activity GO:0051000 9.65 CALM1 CALM3
18 response to corticosterone GO:0051412 9.65 CALM1 CALM3
19 detection of calcium ion GO:0005513 9.65 CALM1 CALM2 CALM3
20 regulation of synaptic vesicle endocytosis GO:1900242 9.64 CALM1 CALM3
21 establishment of protein localization to membrane GO:0090150 9.64 CALM1 CALM3
22 response to denervation involved in regulation of muscle adaptation GO:0014894 9.63 DAG1 DMD
23 negative regulation of ryanodine-sensitive calcium-release channel activity GO:0060315 9.63 CALM1 CALM2 CALM3
24 Schwann cell differentiation GO:0014037 9.62 DAG1 LAMA2
25 mitotic nuclear envelope reassembly GO:0007084 9.62 EMD LMNA
26 regulation of heart rate GO:0002027 9.62 CALM1 CALM2 CALM3 DMD
27 regulation of high voltage-gated calcium channel activity GO:1901841 9.61 CALM1 CALM3
28 positive regulation of ryanodine-sensitive calcium-release channel activity GO:0060316 9.61 CALM1 CALM2 CALM3
29 establishment of protein localization to mitochondrial membrane GO:0090151 9.58 CALM1 CALM3
30 regulation of cell communication by electrical coupling involved in cardiac conduction GO:1901844 9.58 CALM1 CALM2 CALM3
31 positive regulation of cyclic-nucleotide phosphodiesterase activity GO:0051343 9.43 CALM1 CALM2 CALM3
32 positive regulation by host of symbiont cAMP-mediated signal transduction GO:0075206 9.33 CALM1 CALM2 CALM3
33 regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion GO:0010881 9.26 CALM1 CALM2 CALM3 DMD
34 regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0010880 8.92 CALM1 CALM2 CALM3 DMD

Molecular functions related to Cardiomyopathy, Dilated, 1a according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 calcium ion binding GO:0005509 9.93 CALM1 CALM2 CALM3 DAG1 HPGDS SNCA
2 protein kinase binding GO:0019901 9.9 CALM1 CALM2 CALM3 SREBF1
3 actin binding GO:0003779 9.86 DAG1 DMD EMD SNCA
4 protein domain specific binding GO:0019904 9.8 CALM1 CALM2 CALM3 SNCA
5 ion channel binding GO:0044325 9.75 CALM1 CALM2 CALM3
6 protein N-terminus binding GO:0047485 9.74 CALM1 CALM3 SNCA
7 disordered domain specific binding GO:0097718 9.65 CALM1 CALM2 CALM3
8 enzyme regulator activity GO:0030234 9.61 CALM1 CALM3
9 phosphatidylinositol 3-kinase binding GO:0043548 9.58 CALM1 CALM3
10 protein serine/threonine kinase activator activity GO:0043539 9.58 CALM1 CALM2 CALM3
11 calcium channel inhibitor activity GO:0019855 9.55 CALM1 CALM2
12 vinculin binding GO:0017166 9.54 DAG1 DMD
13 nitric-oxide synthase binding GO:0050998 9.54 CALM1 CALM3 DMD
14 dystroglycan binding GO:0002162 9.52 DAG1 DMD
15 nitric-oxide synthase regulator activity GO:0030235 9.51 CALM1 CALM3
16 titin binding GO:0031432 9.5 CALM1 CALM2 CALM3
17 type 3 metabotropic glutamate receptor binding GO:0031800 9.43 CALM1 CALM3
18 adenylate cyclase binding GO:0008179 9.43 CALM1 CALM2 CALM3
19 protein phosphatase activator activity GO:0072542 9.33 CALM1 CALM2 CALM3
20 adenylate cyclase activator activity GO:0010856 9.13 CALM1 CALM2 CALM3
21 N-terminal myristoylation domain binding GO:0031997 8.8 CALM1 CALM2 CALM3
22 protein binding GO:0005515 10.37 CALM1 CALM2 CALM3 DAG1 DMD EMD

Sources for Cardiomyopathy, Dilated, 1a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....